Complement involvement in kidney diseases: From physiopathology to therapeutical targeting

Table 2 Some of the molecules aimed to target complement, phase of the trial and renal diseases related

Compound name	Complement target	Compound class	Phase/indication
C1 inhibitor (Berinert)	C1r, C1s, MASP1, MASP2	Regulator	P 1/2 transplant
Cp40, AMY 101			PC transplant , aHUS, DDD
sCR1, CDX-1135	C3 conv, C4b, C3b	Regulator	P 1 DDD
Mirococept, APT070	C3 conv, C4b, C3b	Regulator	P 1/2 transplant
Eculizumab	C5	Ab	P 4 aHUS, P 2/3 STEC-HUS, P 2 ANCA vasculitis, P 1 transplant
Mubodina	C5	Ab	PC aHUS, DDD
Ergidina	C5	Ab	PC transplant
CCX168	C5aR	Small molecule	P 2 ANCA vasculitis
ADC-1004	C5aR	Protein	PC transplant

MASP1: Mannan-binding lectin-associated serine protease; P: Phase; PC: Preclinical; aHUS: Atypical hemolytic uremic syndrome; DDD: Dense deposit disease; sCR1: Soluble complement receptor 1; Ab: Antibodies; STEC-HUS: Shiga toxin producing Escherichia Coli-hemolytic uremic syndrome.